Loading...
•
Dec 31, 2025
Genmab Q4 2025 Earnings Report
Genmab reported fourth quarter 2025 results with continued royalty-driven revenue growth and sustained profitability.
Key Takeaways
In Q4 2025, Genmab generated revenue of 1058000000 and net profit of 31000000, supported primarily by strong royalty income and product sales while continuing to invest in its late-stage pipeline.
Revenue reached 1058000000 in Q4 2025.
Operating profit was 58000000 for the quarter.
Net profit totaled 31000000 in Q4.
Royalty revenues remained the primary contributor to total revenue.
Forward Guidance
Management expects continued revenue growth in 2026 driven by higher royalties and product sales.
Positive Outlook
- Projected revenue growth in 2026.
- Strong DARZALEX royalty outlook.
- Growth in EPKINLY and Tivdak sales.
- Advancement of late-stage pipeline assets.
- Solid operating profit expectations.
Challenges Ahead
- Higher operating expenses expected in 2026.
- Dependence on collaboration royalties.
- Regulatory and development risks.
- Currency exchange rate sensitivity.
- Milestone timing variability.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...